Compare Sana Biotechnology Inc (SANA) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Wendys Co — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Wendys Co trades at $8.62 (market cap $1.44B). The key difference: Wendys Co is the larger of the two by market cap, and Wendys Co pays a 3.71% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | WEN | |
|---|---|---|
Market Cap | $1.13B | $1.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $10.68 |
52-Week Low | $2.68 | $6.17 |
Enterprise Value | $1.05B | $5.17B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Wendy's (WEN) stock is trading at $8.57, up 17.4% in 24 hours, with a neutral technical signal and bullish moving averages. The company reported Q2 2026 EPS of $0.18, beating expectations, but faces challenges including a 50% dividend cut, withdrawn 2026 outlook, and declining U.S. same-store sales as Burger King overtakes it as the second-largest U.S. burger chain. Financial metrics show a P/E of 11.44 and ROE of 108.04%, but net income margin has fallen to 5.72% for 2026.
The outlook is cautious; while valuation appears reasonable and recent earnings beats are positive, significant operational headwinds, high debt, and intense competition pose risks. Analyst sentiment is mixed with a majority Hold rating, reflecting uncertainty around the new CEO's turnaround plan. Investment opportunity hinges on successful execution of strategic initiatives to restore growth and profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
